XY Capital Ltd Grows Stock Position in Telix Pharmaceuticals Limited $TLX

XY Capital Ltd increased its stake in shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) by 468.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 71,291 shares of the company’s stock after purchasing an additional 58,739 shares during the quarter. Telix Pharmaceuticals accounts for approximately 0.8% of XY Capital Ltd’s holdings, making the stock its 20th biggest position. XY Capital Ltd’s holdings in Telix Pharmaceuticals were worth $822,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Millennium Management LLC acquired a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,883,000. Hennion & Walsh Asset Management Inc. purchased a new position in Telix Pharmaceuticals during the 2nd quarter worth $1,731,000. Portland Investment Counsel Inc. lifted its stake in shares of Telix Pharmaceuticals by 108.0% in the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company’s stock worth $2,063,000 after acquiring an additional 138,200 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Telix Pharmaceuticals by 118.6% in the 4th quarter. Lazard Asset Management LLC now owns 250,517 shares of the company’s stock worth $1,876,000 after acquiring an additional 135,893 shares during the period. Finally, Private Advisor Group LLC boosted its holdings in shares of Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after acquiring an additional 128,070 shares in the last quarter.

Telix Pharmaceuticals Stock Up 1.7%

NASDAQ:TLX opened at $11.94 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals Limited has a fifty-two week low of $6.28 and a fifty-two week high of $12.48. The firm’s fifty day simple moving average is $11.21 and its 200-day simple moving average is $9.96.

Analyst Ratings Changes

TLX has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Wednesday. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Royal Bank Of Canada downgraded Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Telix Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.